Page 49 - 80_01

Elvira
López-­-Oliva
Muñoz,
Emilia
Muñoz
Martínez

199. Musso,
G.,
Gambino,
R.,
Cassader,
M.,
2013.
Cholesterol
metabolism
and
the

pathogenesis
of
non-­-alcoholic
steatohepatitis.
Prog
Lipid
Res
52,
175-­-191.

200. Caballero,
F.,
Fernández,
A.,
De
Lacy,
A.M.
y
col.
2009.
Enhanced
free
cholesterol,

SREBP-­-2
and
StAR
expression
in
human
NASH.
J
Hepatol
50,
789-­-796.

201. Steffensen,
K.R.,
Jakobsson,
T.,
Gustafsson,
J.,
2013.
Targeting
liver
X
receptors
in

inflammation.
Expert
Opin
Ther
Targets
17,
977-­-990.

202. Griffett,
K.,
Solt,
L.A.,
El-­-Gendy,
B.l.-­-D.
y
col.
2013.
A
liver-­-selective
LXR
inverse

agonist
that
suppresses
hepatic
steatosis.
ACS
Chem
Biol
8,
559-­-567.

203. Zhai,
Y.,
Wada,
T.,
Zhang,
B.,
Khadem,
S.,
Ren,
S.,
Kuruba,
R.,
Li,
S.,
Xie,
W.,
2010.
A

functional
cross-­-talk
between
liver
X
receptor-­-a
and
constitutive
androstane
receptor

links
lipogenesis
and
xenobiotic
responses.
Mol
Pharmacol
78,
666-­-674.

204. Roth,
A.,
Looser,
R.,
Kaufmann,
M.
y
col.
2008.
Regulatory
cross-­-talk
between
drug

metabolism
and
lipid
homeostasis:
constitutive
androstane
receptor
and
pregnane
X

receptor
increase
Insig-­-1
expression.
Mol
Pharmacol
73,
1282-­-1289.

205. Eissing,
L.,
Scherer,
T.,
Tödter,
K
y
col.
2013.
De
novo
lipogenesis
in
human
fat
and

liver
is
linked
to
ChREBP-­-ß
and
metabolic
health.
Nat
Commun
4,
1528-­-1549.

48